The massive overhang of up to 433.9M registered shares (22.3x current float) creates severe downward pressure on ENSC. The conversion is contingent on stockholder approval and Nasdaq's $4.00 minimum bid requirement — both are high hurdles given the current $0.50 stock price. Monitor for stockholder meeting announcements and any reverse split proposals. If conversion proceeds, expect extreme dilution. The going concern qualifications in both Ensysce and Cy Biopharma audits underscore the financial distress.
Price Chart
Executive Summary
Ensysce Biosciences filed an S-3 registration statement to register up to 433,907,000 shares of common stock for resale by selling securityholders upon conversion of Series C Non-Voting Convertible Preferred Stock. The shares are issuable in connection with the August 2026 acquisition of Cy Biopharma, a concurrent ~$43M PIPE financing, side letter agreements, and other transactions. The filing does not raise new capital for Ensysce but enables massive potential dilution — the registered shares represent approximately 2,230% of current outstanding common stock (19,456,794 shares as of October 19, 2026). Conversion is contingent on stockholder approval and Nasdaq initial listing process, including a $4.00 minimum bid price requirement, which creates significant execution risk.
Key Facts
- Registers up to 433,907,000 shares of common stock for resale by selling securityholders upon conversion of Series C Preferred Stock.
- Registered shares represent approximately 2,230% of the 19,456,794 shares outstanding as of October 19, 2026.
- Ensysce will not receive any proceeds from the resale; all proceeds go to selling securityholders.
- Conversion of preferred stock requires stockholder approval and Nasdaq initial listing process, including a $4.00 minimum bid price requirement.
- The PIPE financing raised approximately $43 million over two tranches, with 66,811 preferred shares issued at $321.79 per share initially and up to 53,449 more at $402.24 per share subject to a clinical milestone.
- Auditor reports for both Ensysce (Baker Tilly) and Cy Biopharma (EisnerAmper) include going concern uncertainties.
- Lock-up agreements for certain Cy stockholders and Ensysce directors/officers expire 180 days after the August 5, 2026 closing.
- Stock price on October 19, 2026 was $0.5029 per share; market cap ~$10M.
Financial Impact
Potential dilution of up to 2,230% of current shares outstanding, representing up to ~$222M in market value at the $0.5125 reference price used for filing fee calculation. Ensysce receives no proceeds from resales.
Risk Factors
- Extreme dilution of up to 2,230% of current shares outstanding upon conversion of preferred stock.
- Nasdaq delisting risk if $4.00 minimum bid price requirement is not met for initial listing process.
- Going concern uncertainties flagged in both Ensysce and Cy Biopharma audit reports.
- Stockholder approval for conversion may not be obtained, leaving preferred stock unconvertible and creating legal/complexity overhang.
- Lock-up expiration 180 days post-closing (early February 2027) could add further selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-048246 |
| Exhibit: ex107.htm | 0001493152-26-048246 |
| Exhibit: ex5-1.htm | 0001493152-26-048246 |
| Exhibit: ex23-2.htm | 0001493152-26-048246 |
| Exhibit: ex23-3.htm | 0001493152-26-048246 |
| Document: 0001493152-26-048246-index-headers.html | 0001493152-26-048246 |
| Document: 0001493152-26-048246-index.html | 0001493152-26-048246 |
| Document: 0001493152-26-048246.txt | 0001493152-26-048246 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | S-3 | $0.4847 | awaiting T+20 | — | $0.4710 (+2.83%) |
Aug 25, 2026 8w ago | 8-K | $0.4120 $0.4001 | ▲ +2.89% | ▲ +3.11% | $0.4710 (−14.32%) |
Jun 29, 2026 17w ago | EFFECT | $0.2967 $0.2614 | ▲ +11.90% | ▲ +11.62% | $0.4710 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers